Rapid cancer diagnosis for patients with vague symptoms: a cost-effectiveness study.
Bernadette Sewell, Mari Jones, Helen Gray...
https://pubmed.ncbi.nlm.nih.gov/31932296/Actively Recruiting
Led by Royal Marsden NHS Foundation Trust · Updated on 2025-04-17
1000
Participants Needed
10
Research Sites
261 weeks
Total Duration
Rapid Diagnostic Centres RDCs are designed to quickly diagnose patients who show common symptoms that might be related to cancer, such as weight loss, fatigue, cough, or a general practitioners suspicion. This observational study aims to develop new blood or non-blood tests that help doctors identify which patients have cancer and which are at higher risk, so they can be monitored or directed to appropriate screening programs. The study focuses on improving diagnosis and risk assessment in patients referred to RDCs, many of whom may not have cancer but could be at risk due to inherited or environmental factors. The study collects breath, blood, and saliva samples from up to 1000 patients attending RDCs to develop tests that can detect cancer or assess cancer risk through polygenic risk scores. Samples are taken at the first appointment and follow-up visits if necessary. Patients provide consent and are assigned a unique Study ID to keep their information confidential. Clinical data, patient health questionnaires, and, for some, anonymized scans from medical records are also collected to support the development of diagnostic tools. Participants will provide samples and complete health surveys at their visits, with samples shipped to labs for analysis. The study will follow patients for 12 months after joining to confirm diagnoses and observe outcomes. Researchers will analyze clinical, genetic, imaging, and symptom data to develop models that distinguish between cancer and non-cancer cases. Patient data and samples will be stored for ten years to support future research and improved diagnostic methods.
CONDITIONS
RDC Biomarker Study
S
Serwaa Lashley
R
Richard Lee
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Royal Marsden NHS Foundation Trust
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants undergo diagnostic assessments including collection of blood specimens and imaging as part of the Rapid Diagnostic Centre pathway to evaluate suspected cancer presence.
1 baseline visit and up to 3 additional visits for blood specimen collection spaced by at least 21 days
Duration - Up to 12 months following diagnostic evaluation
Participants are observed for clinical outcomes and diagnosis confirmation through surveillance and data collection up to one year after initial diagnostic assessments.
Follow-up visits and data collection as per routine clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Bernadette Sewell, Mari Jones, Helen Gray...
https://pubmed.ncbi.nlm.nih.gov/31932296/S McPhail, S Johnson, D Greenberg...
https://pubmed.ncbi.nlm.nih.gov/25734389/Brian D Nicholson, Willie Hamilton, Constantinos Koshiaris...
https://pubmed.ncbi.nlm.nih.gov/32291391/Biting Zhou, Kailun Xu, Xi Zheng...
https://pubmed.ncbi.nlm.nih.gov/32747657/Amit Sud, Clare Turnbull, Richard Houlston
https://pubmed.ncbi.nlm.nih.gov/34021222/Margaret S Pepe, Christopher I Li, Ziding Feng
https://pubmed.ncbi.nlm.nih.gov/25837819/Samantha Cruz Rivera, Xiaoxuan Liu, An-Wen Chan...
https://pubmed.ncbi.nlm.nih.gov/33328049/Minjoung Monica Koo, Karla Unger-Saldaña, Amos D Mwaka...
https://pubmed.ncbi.nlm.nih.gov/33405957/Diego Ardila, Atilla P Kiraly, Sujeeth Bharadwaj...
https://pubmed.ncbi.nlm.nih.gov/31110349/M C Liu, G R Oxnard, E A Klein...
https://pubmed.ncbi.nlm.nih.gov/33506766/Royal Marsden NHS Foundation Trust
Lead Sponsor